Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

NCT ID: NCT00702507

Last Updated: 2012-03-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether repeated use of 0.25% miconazole nitrate ointment in newborns and infants with a yeast infection in the diaper area causes the yeast to become resistant to the drug.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to investigate the potential for the development of resistance in Candida spp. after repeated treatment courses of 0.25% miconazole nitrate ointment in neonates and infants up to one year of age.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diaper Rash

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Miconazole Nitrate

Group Type ACTIVE_COMPARATOR

0.25 % Miconazole Nitrate Ointment

Intervention Type DRUG

Topical Application

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.25 % Miconazole Nitrate Ointment

Topical Application

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vusion

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female neonate or infant up to 1 year of age with Fitzpatrick Skin Type I-VI
* Clinical evidence of diaper dermatitis and a positive KOH result for pseudohyphae and/or budding yeast at baseline visit
* Overall Diaper Dermatitis Severity Index score at baseline visit of 4-8 (must include an overall clinical grade of at least 2 for erythema)
* Wear commercially available diapers day and night for at least 7 days prior to enrollment and during the course of the 2 year study
* Caretaker must complete informed consent process

Exclusion Criteria

* Known sensitivity to any component of the formulation
* No other skin conditions that may confound the evaluation of the drug efficacy or tolerability
* Known sensitivity to skin care toiletry products or diapers
* History of HIV positive
* Chronic illnesses that require systemic medication that may confound the evaluation of study drug efficacy or tolerability (antibiotic therapy is not included)
* Treatment with a prescription product for diaper dermatitis or other skin condition 7 days prior to enrollment
Maximum Eligible Age

15 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role collaborator

Stiefel, a GSK Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sheila Fallon Friedlander, MD

San Diego, California, United States

Site Status

David Rodriguez, MD

Coral Gables, Florida, United States

Site Status

Lawrence Schachner, MD

Miami, Florida, United States

Site Status

Wilson P. Andrews Jr., MD

Marietta, Georgia, United States

Site Status

Lewis Purnell, MD

San Antonio, Texas, United States

Site Status

Daisy Blanco, MD

Santo Domingo, , Dominican Republic

Site Status

Manuel Briones, MD

Guayaquil, , Ecuador

Site Status

Zila Espinosa, MD

Panama City, , Panama

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Dominican Republic Ecuador Panama

References

Explore related publications, articles, or registry entries linked to this study.

Blanco D, van Rossem K. A prospective two-year assessment of miconazole resistance in Candida spp. With repeated treatment with 0.25% miconazole nitrate ointment in neonates and infants with moderate to severe diaper dermatitis complicated by cutaneous candidiasis. Pediatr Dermatol. 2013 Nov-Dec;30(6):717-24. doi: 10.1111/pde.12107. Epub 2013 May 16.

Reference Type DERIVED
PMID: 23675632 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BT0100-402-USA

Identifier Type: OTHER

Identifier Source: secondary_id

114678

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.